NB
AVNS

NBT Bank’s Avanos Medical AVNS Stock Holding History

NBT Bank’s Portfolio AVNS Stock Details AVNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-20
Closed -$449 – 599
2023
Q4 		$449 Buy
+20
New +$413 ﹤0.01% 578

Other funds holding AVNS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RC
RGM Capital Naples, Florida $2.06B AUM 8.49% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
WHG
Westwood Holdings Group Dallas, Texas $13.7B AUM 21.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
PIM
Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return

NBT Bank's AVNS Position: Q1 2024 in Review

NBT Bank sold out of Avanos Medical (AVNS) in Q1 2024, closing a stake of 20 shares — an estimated $449 sold.

NBT Bank first reported a position in AVNS in Q4 2023 and held it in 1 quarter. The position peaked at $449 in Q4 2023. 261 funds tracked by Wall St. Rank hold AVNS as of Q1 2024.

  • NBT Bank reported no remaining Avanos Medical position as of Q1 2024 after selling out during the quarter.
  • NBT Bank sold 20 Avanos Medical shares in Q1 2024, an estimated $449.
  • NBT Bank first reported a position in Avanos Medical in Q4 2023 and held it in 1 quarter.
  • NBT Bank's Avanos Medical position peaked at $449 in Q4 2023.
  • 261 funds tracked by Wall St. Rank held Avanos Medical as of Q1 2024.

Based on NBT Bank's 13F filing for Q1 2024, filed 24 Apr 2024.